givinostat-hydrochloride has been researched along with givinostat* in 2 studies
2 other study(ies) available for givinostat-hydrochloride and givinostat
| Article | Year |
|---|---|
Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat).
Oncogenic BRAF mutations have been widely described in melanomas and promote tumour progression and chemoresistance. We previously provided evidence that the HDAC inhibitor ITF2357 (Givinostat) targets oncogenic BRAF in SK-MEL-28 and A375 melanoma cells. Here, we show that oncogenic BRAF localises to the nucleus of these cells, and the compound decreases BRAF levels in both the nuclear and cytosolic compartments. Although mutations in the tumour suppressor Topics: Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Melanoma; Mutation; Proto-Oncogene Proteins B-raf; Tumor Suppressor Protein p53 | 2023 |
Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Brain; Carbamates; Cytokines; Humans; Hydroxamic Acids; Hypoxia; Hypoxia-Ischemia, Brain; Infant, Newborn; Inflammation; Ischemia; Rats | 2022 |